Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.41 |
| ▸ | JAK1 | P23458 | 12/20 | 0.41 |
| ▸ | TYK2 | P29597 | 12/20 | 0.41 |
| ▸ | JAK3 | P52333 | 11/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462313 | 0.82 | JAK2 (0.57) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5469730 | 0.82 | TYK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613564 | 0.73 | JAK2 (0.52) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606479 | 0.71 | FYN (0.44) | SRC | |
| SCHEMBL13606569 | 0.70 | JAK2 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5241264 | 0.69 | HTT (0.45) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL13613573 | 0.67 | JAK2 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613530 | 0.66 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606580 | 0.66 | JAK2 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5813228 | 0.66 | CHEK1 (0.42) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | ROCHE PALO ALTO LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | JAK2 85/4885JAK1 48/4885TYK2 207/4885 |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | JAK2 85/4885JAK1 48/4885TYK2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.